Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2056 SAD and Food-Effect Study in Healthy Subjects
NCT07771777Phase 1Not yet recruiting
- Sponsor
- InnovStone Therapeutics
- Start
- Aug 2026
- Primary completion
- Jan 2027
01
Overview
Phase 1, randomised, double-blind trial of SYH2056 (9 arms), sponsored by InnovStone Therapeutics. Primary endpoints: Adverse Events, Blood Pressure and 10 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
SYH2056
Beyond the preview
Go deeper on NCT07771777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07771777.